Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Calliditas Therapeutics AB - ADR?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Calliditas Therapeutics AB - ADR market cap is $1.07B.
What is the 52-week high for Calliditas Therapeutics AB - ADR?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Calliditas Therapeutics AB - ADR 52 week high is $43.00 as of September 10, 2025.
What is the 52-week low for Calliditas Therapeutics AB - ADR?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Calliditas Therapeutics AB - ADR 52 week low is $15.25 as of September 10, 2025.
What is Calliditas Therapeutics AB - ADR stock price today?
Calliditas Therapeutics AB - ADR stock price today is $40.33.
What was Calliditas Therapeutics AB - ADR stock price yesterday?
Calliditas Therapeutics AB - ADR stock price yesterday was $39.99.
What is the PE ratio of Calliditas Therapeutics AB - ADR?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Calliditas Therapeutics AB - ADR’s P/E ratio is -23.64.
What is the Price-to-Book ratio of Calliditas Therapeutics AB - ADR?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Calliditas Therapeutics AB - ADR P/B ratio is 107.1240.
What is the 50-day moving average of Calliditas Therapeutics AB - ADR?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Calliditas Therapeutics AB - ADR 50-day moving average is $39.63.
